Rituximab Pre-Medication and Vaccination Management

Pre-Medication Protocol for Rituximab Infusions

Standard pre-medication with acetaminophen and antihistamine is recommended before each rituximab infusion, though specific corticosteroid pre-medication protocols are not universally mandated by current rheumatology guidelines. 1

Practical Pre-Medication Approach

Acetaminophen 650-1000 mg orally should be administered 30-60 minutes before rituximab infusion 1
Antihistamine (diphenhydramine 25-50 mg orally or IV) should be given 30-60 minutes before infusion 1
Corticosteroid pre-medication is not routinely required for all patients, but may be considered for those with prior infusion reactions 1
Patients already on maintenance glucocorticoids (≤10 mg prednisone daily) do not require additional pre-medication adjustments 1

Vaccination Timing Strategy for Maintenance Rituximab

Critical Principle: Rituximab Profoundly Impairs Vaccine Responses

The cornerstone of vaccination management in rituximab-treated patients is timing vaccines to coincide with maximal B-cell recovery—specifically just before the next scheduled rituximab dose—followed by delaying rituximab for at least 2 weeks post-vaccination. 1, 2

Pre-Rituximab Vaccination (Ideal Scenario)

Vaccines to Administer BEFORE Starting Rituximab

All indicated vaccines should be completed at least 2-4 weeks before rituximab initiation whenever possible, as this provides the best immunogenicity. 1, 3

Pneumococcal Vaccination Series

PCV13 (13-valent pneumococcal conjugate vaccine): Give 8-12 weeks before rituximab initiation 3
PPSV23 (23-valent pneumococcal polysaccharide vaccine): Administer 8 weeks after PCV13, ideally still before rituximab 2, 3
Rationale: Only 19% of rituximab-treated patients achieve adequate pneumococcal antibody response (≥2-fold rise in ≥6 serotypes) versus 61% of controls 2

Other Essential Pre-Rituximab Vaccines

Seasonal inactivated influenza vaccine: Give at least 2 weeks before rituximab 3
Tdap (tetanus-diphtheria-pertussis): Ensure up-to-date, give at least 2 weeks before rituximab if due 3
Hepatitis B series: Initiate 8-12 weeks before rituximab if non-immune 3
Recombinant zoster vaccine (Shingrix): Complete 2-dose series before rituximab if patient ≥50 years 2

Live Vaccines (Must Be Given BEFORE Rituximab)

MMR booster: Administer at least 4 weeks before rituximab initiation if lacking documented immunity 1, 3
Varicella vaccine: Give at least 4 weeks before rituximab if non-immune 1
Live vaccines are absolutely contraindicated once rituximab is started or within 6 months after the last dose 2, 3

Vaccination During Maintenance Rituximab Therapy

Algorithm for Timing Inactivated Vaccines

For patients already on maintenance rituximab, the vaccination strategy differs based on vaccine type and urgency.

Influenza Vaccination (Exception to the Rule)

Administer annual inactivated influenza vaccine on its seasonal schedule WITHOUT delaying rituximab, because public health urgency outweighs reduced immunogenicity. 1, 2

Give the vaccine when seasonally appropriate (typically September-November in Northern Hemisphere) 2
Do NOT hold or delay the next rituximab dose after influenza vaccination 1
Use high-dose quadrivalent inactivated formulation for patients ≥65 years or immunocompromised to improve response 2
Never use live attenuated intranasal influenza vaccine in rituximab-treated patients 2
Expect suboptimal response: influenza vaccine responses are significantly blunted by rituximab, with only 16% of patients achieving 4-fold titer increase 4

All Other Inactivated Vaccines (Pneumococcal Boosters, Tdap, Hepatitis B, COVID-19, Shingrix)

Defer these vaccines until the visit when the next rituximab infusion is scheduled, then vaccinate and delay rituximab by at least 2 weeks. 1, 2

Step-by-Step Protocol:

Schedule vaccination for the same day the next rituximab dose is due 2
Administer the vaccine(s) first 2
Postpone the rituximab infusion by at least 2 weeks (14 days minimum) to allow antibody development 1, 2
Only delay rituximab if disease activity permits—if active disease flare is imminent, proceed with rituximab and accept suboptimal vaccine response 1

Immunologic Rationale:

B-cell counts reach their nadir immediately after rituximab and gradually recover over 6 months 2, 5
Vaccinating just before the next scheduled dose exploits the period of maximal B-cell recovery 2
The 2-week delay allows time for vaccine-specific B cells to proliferate and differentiate into antibody-producing plasma cells before rituximab re-depletes them 1, 2

Specific Vaccine Schedules on Maintenance Rituximab

Pneumococcal Booster Schedule

If the patient previously received PCV13 but not PPSV23, administer PPSV23 now using the optimal timing strategy (just before next rituximab, then delay rituximab ≥2 weeks). 2

Standard pneumococcal sequence: PCV13 → wait 8 weeks → PPSV23 → wait 5 years → second PPSV23 2
If both PCV13 and first PPSV23 already given: Next PPSV23 booster is due 5 years after the first PPSV23 2
Measure pneumococcal serotype-specific antibodies 4 weeks after PPSV23 to verify response 1, 2

Tetanus Toxoid Boosters

Administer Tdap every 10 years using the optimal timing strategy. 2, 3

Special consideration for contaminated wounds: If rituximab was given within the past 6 months, administer tetanus immunoglobulin in addition to Tdap, because vaccine response may be inadequate 1

COVID-19 Vaccination

Follow the general population schedule for COVID-19 vaccines, using the optimal timing strategy (vaccinate just before next rituximab, delay rituximab ≥2 weeks). 2

Recent pediatric data suggest that prior SARS-CoV-2 infection may enable adequate antibody response even with shorter rituximab-to-vaccine intervals (<6 months), likely due to memory B-cell reactivation 6
However, in the absence of documented prior infection, adhere to the standard timing protocol 2

Recombinant Zoster Vaccine (Shingrix)

Administer the 2-dose series (doses separated by 2-6 months) using the optimal timing strategy for each dose. 2

This is an inactivated vaccine and safe during rituximab therapy 2
Time each dose just before the next rituximab infusion, then delay rituximab ≥2 weeks 2

Glucocorticoid Co-Therapy Considerations

Impact of Concurrent Glucocorticoids on Vaccine Response

Low-dose glucocorticoids (≤10 mg prednisone daily) do not significantly impair vaccine responses when combined with rituximab. 1, 2

Prednisone ≤10 mg/day: Proceed with all non-live vaccines as scheduled 1
Prednisone >10 mg but <20 mg/day: Proceed with vaccination, though response may be slightly reduced 1
Prednisone ≥20 mg/day for ≥2 weeks: Consider deferring non-influenza vaccines until glucocorticoid dose is tapered below 20 mg/day, as high-dose steroids further impair already-compromised vaccine responses in rituximab-treated patients 1, 2

Post-Vaccination Antibody Monitoring

When to Check Titers

Measure pathogen-specific antibody concentrations approximately 4 weeks after vaccination in all rituximab-treated patients to verify adequate immune response. 1, 2

Specific Antibodies to Measure:

After pneumococcal vaccination: Pneumococcal serotype-specific antibodies (≥2-fold rise in ≥6 serotypes indicates adequate response) 1, 2
After tetanus vaccination: Tetanus toxoid antibodies 1, 2
After hepatitis B vaccination: Hepatitis B surface antibody (anti-HBs) 3
After influenza vaccination: Hemagglutination inhibition titers (though clinical utility is limited) 4

Management of Inadequate Response

If antibody titers are insufficient, consider revaccination after rituximab discontinuation or during a prolonged treatment holiday, though evidence for this approach is limited. 2

Patients with chronic rituximab-induced hypogammaglobulinemia (low IgG and/or IgM) are at highest risk for vaccine failure 7
Hypogammaglobulinemia correlates more strongly with vaccine non-response than B-cell counts or timing of vaccination 7

Absolute Contraindications During Rituximab Therapy

Live Attenuated Vaccines

Live vaccines must NEVER be administered during rituximab therapy or within 6 months after the last rituximab dose due to severe immunosuppression and risk of vaccine-strain infection. 1, 2, 3

Contraindicated Live Vaccines:

MMR (measles-mumps-rubella) 1, 3
Varicella (chickenpox) 1, 3
Live attenuated zoster (Zostavax—note: recombinant Shingrix is safe) 2
Live attenuated intranasal influenza vaccine (FluMist) 2
Yellow fever vaccine 1
Oral typhoid vaccine 3
BCG (bacille Calmette-Guérin) 1

Common Pitfalls and How to Avoid Them

Pitfall 1: Vaccinating Immediately After Rituximab Infusion

Problem: B-cell counts are at nadir; vaccine response is minimal to absent 2, 5
Solution: Always wait until just before the next rituximab dose is due 2

Pitfall 2: Failing to Delay Rituximab After Vaccination

Problem: Rituximab re-depletes B cells before antibody response can develop 1, 2
Solution: Mandatory ≥2-week delay between vaccination and next rituximab dose 1, 2

Pitfall 3: Deferring Influenza Vaccine to Optimize Timing

Problem: Patient misses seasonal window and remains unprotected during influenza season 1, 2
Solution: Give influenza vaccine on schedule regardless of rituximab timing 1, 2

Pitfall 4: Assuming Prior Vaccinations Provide Lasting Protection

Problem: Rituximab can deplete existing antibody-producing plasma cells over time, eroding pre-existing immunity 2
Solution: Check antibody titers periodically and consider booster doses using optimal timing strategy 2

Pitfall 5: Administering Live Vaccines Too Soon After Rituximab

Problem: Risk of vaccine-strain infection due to profound immunosuppression 1, 3
Solution: Wait at least 6 months after last rituximab dose before considering any live vaccine 1, 2, 3

Summary Table: Vaccination Timing on Maintenance Rituximab

Vaccine Type	Timing Strategy	Rituximab Delay Required	Key Considerations
Influenza (inactivated)	Give on seasonal schedule	NO delay	Use high-dose formulation if ≥65 years [2]
Pneumococcal (PCV13, PPSV23)	Just before next rituximab dose	≥2 weeks	Check serotype-specific antibodies 4 weeks post-vaccination [2]
Tdap	Just before next rituximab dose	≥2 weeks	Give tetanus immunoglobulin for contaminated wounds if rituximab within 6 months [1]
Hepatitis B	Just before next rituximab dose	≥2 weeks	Check anti-HBs titer 4 weeks post-vaccination [3]
COVID-19	Just before next rituximab dose	≥2 weeks	Follow general population schedule [2]
Recombinant zoster (Shingrix)	Just before next rituximab dose (each dose)	≥2 weeks	Safe inactivated vaccine [2]
Live vaccines (MMR, varicella, etc.)	CONTRAINDICATED	N/A	Wait ≥6 months after last rituximab dose [1,2,3]

Special Populations

Pediatric Patients on Rituximab

The same vaccination timing principles apply to children, with additional emphasis on completing routine childhood immunizations before rituximab initiation whenever possible. 1

Varicella immunity is critical: Assess VZV infection and vaccination history before starting rituximab; vaccinate if non-immune 1
MMR boosters on low-dose methotrexate (<15 mg/m²/week) are safe, but this does not apply to rituximab 1
Yellow fever vaccine boosters may be considered in children on low-dose immunosuppression, but are contraindicated during rituximab 1

Patients with Hypogammaglobulinemia

Rituximab-induced chronic hypogammaglobulinemia (low IgG and/or IgM) is the strongest predictor of vaccine failure, independent of B-cell counts or timing. 7

Monitor immunoglobulin levels periodically during maintenance rituximab 7
Consider IVIG (intravenous immunoglobulin) replacement if recurrent infections occur with persistent hypogammaglobulinemia 1
Even with optimal vaccine timing, patients with hypogammaglobulinemia may not respond adequately 7

Patients on Multiple Immunosuppressants

Concurrent methotrexate, azathioprine, or other DMARDs do not significantly worsen vaccine responses beyond the impairment caused by rituximab alone. 1, 5

Methotrexate: Can be continued during vaccination; holding methotrexate for 2 weeks after influenza vaccination improves response in non-rituximab patients, but this benefit is unclear in rituximab-treated patients 1
High-dose glucocorticoids (≥20 mg prednisone daily): Additive impairment; defer non-influenza vaccines until tapered if possible 1, 2

Hepatitis B Prophylaxis

All rituximab-treated patients who are hepatitis B core antibody positive must receive prophylactic antiviral therapy before starting rituximab to prevent reactivation. 8

Screen for hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), and hepatitis B core antibody (anti-HBc) before rituximab initiation 8
If anti-HBc positive (regardless of HBsAg status), start entecavir or tenofovir prophylaxis 8
Continue antiviral prophylaxis throughout rituximab therapy and for at least 6-12 months after the last dose 8

What are the recommended pre‑medication (antihistamine, acetaminophen, corticosteroid) protocol and vaccination schedule (timing of inactivated and live vaccines) for patients receiving maintenance rituximab therapy?

Help us tailor your experience